Levodrop (Levodropropizine)

Levodropropizine acts on peripheral sensory nerve endings in the respiratory tract. By inhibiting the activation of cough‑triggering receptors, it lowers the sensitivity of the cough reflex without affecting the central nervous system, providing cough suppression with minimal sedation.

The dosage of Levodrop is determined by the prescribing clinician based on the patient’s age, weight, severity of cough, and renal function. Typical adult regimens range from 30 mg to 60 mg taken two to three times daily, but exact dosing must follow the prescriber’s order.

Safety data for levodropropizine in pregnancy and lactation are limited. It should only be used when the expected benefit outweighs potential risks to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Levodrop, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levodrop (levodropropizine) is a peripheral antitussive, whereas agents such as codeine act centrally on the brainstem. Levodrop typically causes fewer central side effects like drowsiness or dependence, but its efficacy is limited to reducing cough reflex sensitivity rather than providing strong analgesic effects.

Levodrop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability and potency throughout its shelf life.

Levodrop is taken orally. The tablet or liquid should be swallowed whole with a glass of water, preferably after meals to reduce gastrointestinal irritation. Patients should follow the prescriber’s instructions regarding frequency and duration of therapy.

Serious adverse reactions, although rare, include severe allergic responses such as rash, urticaria, angioedema, and anaphylaxis. Hepatic dysfunction and hematologic abnormalities like neutropenia have also been reported. Immediate medical attention is required if any of these symptoms develop.

Levodrop is contraindicated in individuals with known hypersensitivity to levodropropizine or any excipients in the formulation. Caution is advised for patients with severe renal impairment, uncontrolled cardiac arrhythmias, or those taking multiple central nervous system depressants.